Société des Industries Pharmaceutiques de Tunisie - S.A. (BVMT: SIPHA)

Market Cap	10.80M
Revenue (ttm)	20.23M
Net Income (ttm)	-17.10M
Shares Out	1.80M
EPS (ttm)	-9.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99
Open	6.00
Previous Close	6.00
Day's Range	6.00 - 6.00
52-Week Range	3.75 - 6.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About SIPHA

Société des Industries Pharmaceutiques de Tunisie - S.A. engages in the research, development, manufacture, packaging, and marketing of pharmaceutical products for human use in Tunisia and internationally. It provides rheumatology drugs, such as MYORELAX, NIFLUMIC, and ALGESAL SURACTIVE; stomatology drugs, including HEXABAIN; and ANALGAN CODEINE 300mg/25mg indicated for the symptomatic treatment of moderate and intense pain. The company was founded in 1989 and is headquartered in Ben Arous, Tunisia.

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 744
• Stock Exchange: Tunis Stock Exchange
• Ticker Symbol: SIPHA

Financial Performance

In 2019, SIPHA's revenue was 24.40 million, a decrease of -26.47% compared to the previous year's 33.19 million. Losses were -14.52 million, 1.81% more than in 2018.